Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth Wydase discontinued

Executive Summary

Wyeth has discontinued production of ocular surgery treatment Wydase (hyaluronidase). Wydase was manufactured at the company's Marietta, Penn. facility, which has been under an FDA consent decree since October 2000 (1"The Pink Sheet" Oct. 9, 2000, p. 3). Wyeth informed FDA of the discontinuation in the fourth quarter of 2000, but agreed to continue to manufacture the product until an alternate supplier of hyaluronidase was found...

You may also be interested in...

ISTA Vitrase Spreading Agent Clears FDA; Full Launch Awaits New Vial

ISTA Pharmaceuticals will delay full-scale launch of its spreading agent Vitrase until it receives approval for a more convenient vial form

Wyeth Will Lose 18.5% Of Marietta Sales If Firm Does Not Comply With GMPs

Wyeth-Ayerst would have to pay the government 18.5% of future net sales from products manufactured at its Marietta, Penn. facility if it fails to meet a timeline for bringing the plant into compliance with current Good Manufacturing Practices under an Oct. 3 consent decree with FDA.

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts